Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jul 22.

Published in final edited form as: Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec 22;387(4):329–339. doi: 10.1007/s00210-013-0950-4

Fig. 3 — a: IL-6 protein production in response to Gα_s-coupled receptor agonists. BSMC were treated with the indicated drug for 24 h, and IL-6 secreted into culture media was measured by ELISA. 1μM Fsk, AVP, CGRP, glucagon, PGD₂, substance P; 10 μM ATPƔS, BRL 37344, NECA. cAMP measured by EIA. b: cAMP production in response to Gα_s – coupled receptor agonists. BSMC were pretreated with 0.2 mM IBMX prior to 10 min agonist exposure: 1μM Fsk, AVP, CGRP, glucagon, PGD₂, substance P; or 10 μM ATPƔS, BRL 37344, NECA. cAMP was measured by EIA. Dashed line represents basal level. Mean ± SEM, n=3–4. * indicates p<.05 compared to vehicle

Fig. 3 — a: IL-6 protein production in response to Gα_s-coupled receptor agonists. BSMC were treated with the indicated drug for 24 h, and IL-6 secreted into culture media was measured by ELISA. 1μM Fsk, AVP, CGRP, glucagon, PGD₂, substance P; 10 μM ATPƔS, BRL 37344, NECA. cAMP measured by EIA. b: cAMP production in response to Gα_s – coupled receptor agonists. BSMC were pretreated with 0.2 mM IBMX prior to 10 min agonist exposure: 1μM Fsk, AVP, CGRP, glucagon, PGD₂, substance P; or 10 μM ATPƔS, BRL 37344, NECA. cAMP was measured by EIA. Dashed line represents basal level. Mean ± SEM, n=3–4. * indicates p<.05 compared to vehicle